Inclusion Criteria:

- Male or female ≥ 20 and <80 years of age

- Patients who has diagnosed as Chemotherapy-Induced Peripheral Neuropathy by
investigator's judgment

- Patient who are receiving pregabalin for the treatment of Chemotherapy-Induced
Peripheral Neuropathy

- Patients who have moderate to severe pain intensity which is not controlled with
300mg of pregabalin per day for at least 1 week: NRS ≥ 4

- Patients who need opioid combination treatment with existing pregabalin treatment

- Naïve patients for strong opioid (Naïve patient defined as who did not treated for 90
days)

- Patients who signed a written informed consent form

Exclusion Criteria:

- Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant. UNLESS they are:

- women whose partners have been sterilized by vasectomy or other means

- two birth control methods. The two methods can be a double barrier method or a
barrier method plus a hormonal method. Adequate barrier methods of contraception
include: diaphragm, condom (by the partner), intrauterine device (copper or
hormonal), sponge or spermicidal. Hormonal contraceptives include any marketed
contraceptive agent that includes an estrogen and/or (Progest - progesterone)
progestational agent.

- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive urine pregnancy test

- Patients with known hypersensitivity to Oxycodone or Naloxone or to any of the
excipients

- Patients with severe respiratory depression with hypoxia and/or hypercapnoea

- Patients with severe chronic obstructive pulmonary disease

- Patients with cor pulmonale

- Patients with severe bronchial asthma

- Patients with non-opioid induced paralytic ileus

- Patients with moderate to severe hepatic impairment

- Targin product contains lactose. Patients with rare hereditary problems of galactose
intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not
take

- Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT;
SGPT), or alkaline phosphatase levels (>2.5 times the upper limit of normal, it is
allowed >5 times the upper limit of normal in case of transition in liver) or an
abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper
limit of normal), gamma glutamyl transpeptidase (GGT or GGTP) ≥ 3 times the upper
limit of normal

- Patients with uncontrolled seizures

- Requiring interventional treatment for pain such as neurodestructive procedure or
regional infusion

- Patients with increased intracranial pressure

- In the investigator's opinion, subjects who are receiving hypnotics or other central
nervous system (CNS) depressants that may pose a risk of additional CNS depression
with opioid study medication

- Patients with myxodema, not adequately treated hypothyroidism or Addison's disease

- Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone
or buprenorphine)

- Clinically significant impairment of cardiovascular, respiratory and renal function

- Major surgery within 1 month prior to screening or planned surgery

- Chemotherapy or radiotherapy within 2 weeks prior to the screening visit, or planned
chemotherapy or radiotherapy during the study period.

- Mainly pain originated other than Chemotherapy-Induced Peripheral Neuropathy

- Patients with diabetic neuropathy

- With a disability that may prevent the patient from completing all study requirements
and in particular, interfere with 24hrs pain intensity score

- Patients known to have, or suspected of having a history of drug abuse

- Patients with history of opioid or drug dependence

- Any situation where opioids are contraindicated

- Having used other investigational drugs at the time of enrollment, or within 30 days
of enrollment